Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shedding and immune response of rotavirus vaccine (RotaTeq)
2014-004252-60Phase 4Completed
- Sponsor
- Tampere University
- Start
- Nov 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rotavirus vaccine, live, oral, pentavalent in rotaviral diarrhea, sponsored by Tampere University. Primary endpoint: Shedding of RotaTeq vaccine in stools and relationship to serum IgA levels. Started Nov 2014; status: completed.
02
Drugs
rotavirus vaccine, live, oral, pentavalent
03
Conditions
rotaviral diarrhea
Beyond the preview
Go deeper on 2014-004252-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004252-60.